Pharvaris (NASDAQ:PHVS - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $14.50, but opened at $15.17. Pharvaris shares last traded at $14.73, with a volume of 1,950 shares trading hands.
Wall Street Analyst Weigh In
Separately, JMP Securities increased their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Friday, January 31st.
Get Our Latest Stock Report on Pharvaris
Pharvaris Stock Up 5.5 %
The company has a market capitalization of $872.98 million, a PE ratio of -5.96 and a beta of -2.84. The firm has a 50-day moving average of $14.94 and a two-hundred day moving average of $18.11.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06. Equities analysts predict that Pharvaris will post -2.71 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharvaris
Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its holdings in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after purchasing an additional 189,714 shares during the period. Soleus Capital Management L.P. lifted its position in shares of Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after buying an additional 216,483 shares in the last quarter. Octagon Capital Advisors LP grew its stake in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after acquiring an additional 157,530 shares during the period. Rock Springs Capital Management LP increased its holdings in Pharvaris by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock worth $14,859,000 after acquiring an additional 18,200 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after acquiring an additional 118,408 shares during the period.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Stories
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
